Skip to content
Parker Institute for Cancer Immunotherapy
Search Close

Justin Fairchild, MPH

Vice President, Clinical Development

Clinical Development


Justin Fairchild, MPH, has 15 years of oncology drug development experience contributing to early and late stage clinical studies of a broad range of approved drugs including cetuximab, dasatinib, ipilimumab and nivolumab across multiple cancer indications. Justin is the vice president of clinical development at PICI where he is responsible for a cross functional team, overseeing clinical trial execution and the delivery of novel immunotherapy clinical studies.

Previously he was at Bristol-Myers Squibb for 14 years in both clinical operations and clinical development where he most recently played a key role in achieving FDA approval of nivolumab for the treatment of small cell lung cancer. Prior to joining BMS, Justin worked in the oncology clinical trials department at Greater Baltimore Medical Center and as a discovery chemist at Pfizer.

He received an MPH from Johns Hopkins School of Public Health, and a BA in chemistry from Colgate University.